DiaMedica Therapeutics (DMAC) to Release Earnings on Wednesday

DiaMedica Therapeutics (NASDAQ:DMAC) will release its earnings data after the market closes on Wednesday, August 7th. Analysts expect DiaMedica Therapeutics to post earnings of ($0.16) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.02. On average, analysts expect DiaMedica Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

DiaMedica Therapeutics Price Performance

NASDAQ DMAC traded down $0.10 during trading hours on Tuesday, hitting $3.35. The company’s stock had a trading volume of 18,426 shares, compared to its average volume of 50,318. The company’s 50 day simple moving average is $2.97 and its two-hundred day simple moving average is $2.90. The company has a market cap of $143.18 million, a P/E ratio of -6.16 and a beta of 1.50. DiaMedica Therapeutics has a 12 month low of $1.94 and a 12 month high of $3.81.

Insider Activity at DiaMedica Therapeutics

In related news, major shareholder Koch Thomas Von acquired 1,200,000 shares of the business’s stock in a transaction that occurred on Friday, June 28th. The stock was bought at an average cost of $2.50 per share, for a total transaction of $3,000,000.00. Following the purchase, the insider now owns 5,526,435 shares in the company, valued at approximately $13,816,087.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 7.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Separately, Craig Hallum assumed coverage on DiaMedica Therapeutics in a research note on Wednesday, April 24th. They set a “buy” rating and a $8.00 price target for the company.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.